2026
article
OpenAlex
M C Boshkos, Amgad Muneer, Eman Showkatian, Felipe Soto et autres
e20531 Background: Interstitial lung abnormalities (ILAs) are established risk factors for immune checkpoint inhibitor–related pneumonitis (ICI-P), but qualitative ILA assessment is subjective. We evaluated whether quantitative lung fibrosis (QLF) metrics from pretreatment computed tomography (CT) are associated with ICI-P in patients with …
us
(code pays fourni par la source)
2026
article
OpenAlex
M C Boshkos, Amgad Muneer, E Showkatian, F Soto et autres
Abstract Rationale Interstitial lung abnormalities (ILAs) are established risk factors for immune checkpoint inhibitor-related pneumonitis (ICI-P), but qualitative ILA assessment is subjective. We evaluated whether quantitative lung fibrosis (QLF) metrics from pre-treatment computed tomography (CT) predict ICI-P in patients with non-small cell …
us
(code pays fourni par la source)
2026
article
OpenAlex
M M A, S Forsythe, F A Camacho, G Gaskey et autres
Abstract Rationale Patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemoradiation (CRT) and immune checkpoint inhibitors (ICI) are at high risk for developing ICI pneumonitis (ICI-P). Prior studies suggest that pre-treatment interstitial lung abnormalities (ILAs) increase the risk …
us
(code pays fourni par la source)
2026
article
OpenAlex
G Gaskey, G Mensah, M Aiche, S Forsythe et autres
Abstract Rationale Pneumonitis is an immune-related adverse event from checkpoint inhibitors that increases morbidity and mortality. Pneumonitis occurs in about 33% of patients receiving concurrent chemotherapy/radiation followed by immunotherapy (CRT-ICI). We investigated whether patient-reported outcomes (PROs) such as the MD Anderson Symptom …
us
(code pays fourni par la source)